TABLE 2.
The role of ANXA3 in therapy resistance.
| Therapy resistance | Years | Tumor types | Main findings | References |
|---|---|---|---|---|
| Platinum resistance | 2020 | Non-small cell lung carcinoma | Anxa3-silencing siRNAs can eliminate oxaliplatin resistance in A549 NSCLC cells | Jin et al. (2020) |
| 2019 | Non-small cell lung carcinoma | ANXA3 secreting CAF induces cisplatin resistance in NSCLC cells A549, H661 and SK-MES-1. The putative mechanism is the activation of JNK/survivin pathway | Wang et al. (2019) | |
| 2019 | Colorectal carcinoma | Depletion of ANXA3 in oxaliplatin resistant HCT116 and SW480 colorectal cancer cells inhibits the cell viability and BrdU incorporation, increases apoptosis and diminishes migration and invasion | Xu et al. (2019) | |
| 2015 | Hepatocellular carcinoma | Increasing resistance to cisplatin in ANXA3-overexpressing tumor cells in vitro and in mouse xenografts in vivo | Pan et al. (2015b) | |
| 2012 | Ovarian carcinoma | Lower intracellular accumulation and DNA binding of cisplatin and carboplatin in ANXA3 overexpressing ovarian cancer cells, accompanied by decreased p53 levels | Yin et al. (2012) | |
| TKIs resistance | 2018 | Hepatocellular carcinoma cells | ANXA3 overexpression inhibits PKC/p38-mediated apoptosis and actives p38-mediated autophagy in sorafenib-resistant HepG2 and Huh7 HCC cells as well as in patient-derived xenografts | Tong et al. (2018) |
| 2013 | 45 cell lines | ANXA3 is associated with resistance against gefitinib, sorafenib, sunitinib and lapatinib | Pénzváltó et al. (2013) | |
| Fluoropyrimidine resistance | 2015 | Hepatocellular carcinoma cells | Overexpressed ANXA3 significantly enhanced the IC50 of 5-FU in both cell-line models and mouse xenografts models | Pan et al. (2015b) |
| 2015 | Gastric cancer | SNP rs2867461 in the ANXA3 gene is significantly correlated with the sensitivity against fluoropyrimidine | Takahashi et al. (2015) | |
| Cyclophosphamide resistance | 2013 | Prostate cancer | ANXA3 expression in cyclophosphamide (CPA)-resistant PC3-D3 and PC3-D4 prostate cancer cells is higher compared to the chemo-sensitive wild type PC3 cell line | Kubisch et al. (2013) |
| 2010 | Thoenes et al. (2010) | |||
| Doxorubicin and docetaxel | 2018 | Triple negative breast cancer | ANXA3 knockdown promotes the uptake of doxorubicin and sensitizes response to doxorubicin and docetaxel | Du et al. (2018) |